Corcept initiates study of nenocorilant with nivolumab in advanced solid tumors
Corcept Therapeutics is conducting a dose-finding study of nenocorilant combined with nivolumab in advanced solid malignancies.
| Drug | MOA / Company | Stage |
|---|---|---|
| nivolumab | Corcept Therapeutics | Lead |
Focal Asset
nivolumab
Company
Corcept Therapeutics
Indication
Oncology / Combination Therapy
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of this trial by Corcept Therapeutics is significant as it explores a new combination therapy in a highly competitive oncology market. Success could enhance Corcept's portfolio and alter competitive dynamics among existing PD-1 inhibitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for results on safety and tolerability, as well as updates on MTD and optimal dosing outcomes.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.